Darbepoetin alfa and chronic kidney disease
Minnerup, J.; Schäbitz, W-Rüdiger.
New England Journal of Medicine 362(7): 653
2010
ISSN/ISBN: 0028-4793 PMID: 20187258 Document Number: 640511
Document emailed within 1 workday
Related Documents
Hampl, H.; Kovesdy, C.P.; Kalantar-Zadeh, K. 2010: Darbepoetin alfa and chronic kidney disease New England Journal of Medicine 362(7): 654; Author Reply 655Locatelli, F.; Vecchio, L.D. 2001: Darbepoetin alfa. Amgen Current Opinion in Investigational Drugs 2(8): 1097-1104
Yuksel, O.H.; Yildirim, C.; Urkmez, A.; Ozbay, N.; Uruc, F.; Sahin, A.; Akan, S.; Verit, A. 2018: The effect of darbepoetin alfa on renal fibrosis in rats with acute unilateral ureteral obstruction Archivos Espanoles de Urologia 71(2): 212-221
Vansteenkiste, J.; Poulsen, E.; Rossi, G.; Glaspy, J. 2002: Darbepoetin alfa: impact on treatment for chemotherapy-induced anemia and considerations in special populations Oncology 16(10 Suppl 11: 45-55
Campistol, J.M.; Carreño, Aín.; Morales, Jé.M.; Pallardó, L.; Franco, A.; Navarro, D.; Grinyó, J.M.; Montenegro, Jús.; Sánchez Fructuoso, A.I.; Romero, Rón.; Guirado, L.; Arias, M.; Nieto-Iglesias, J.; Esforzado, N.; Beltrán-Catalán, S.; Gómez-Alamillo, C.; Lauzurica, R.; Bengoa, I.; Facundo-Molas, C. 2013: Once-monthly pegylated epoetin Beta versus darbepoetin alfa every two weeks in renal transplant recipients: a randomized trial Transplantation 95(2): E6
Nevens, F.; Van Vlierberghe, H.; D'Heygere, E.; Delwaide, J.; Adler, M.; Henrion, J.; Lenaerts, A.; Hendlisz, A.; Michielsen, P.; Bastens, B.; Brenard, R.; Laureys, A. 2010: A randomized, open-label, multicenter study evaluating the efficacy of peginterferon alfa-2a versus interferon alfa-2a, in combination with ribavirin, in naïve and relapsed chronic hepatitis C patients Acta Gastro-Enterologica Belgica 73(2): 223-228
Zhang, L.-x.; Wang, H.-y. 2012: The present situation and challenges of chronic kidney disease in China: an enlightenment from the epidemiological survey of chronic kidney disease in China Zhonghua Nei Ke Za Zhi 51(7): 497-498
Wong, J. B.; Nevens, F. 2002: Cost-effectiveness of peginterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin as initial treatment of chronic hepatitis C in Belgium Acta Gastro-Enterologica Belgica 65(2): 110-111
Fernández, I.; Castellano, G.; Canga, F.; Colina, F.; García, H.; Fuertes, A.; Casis, B.; Martín, A.; Solís, J.A. 1995: A comparative randomized controlled study of the efficacy of interferon alfa-2b and interferon alfa-2a in the treatment of chronic hepatitis C Gastroenterologia y Hepatologia 18(2): 66-72
Gorostidi, M.; Marín, R. 2004: Antihypertensive therapy in early stages of chronic kidney disease. Second and third stages of chronic kidney disease Nefrologia: Publicacion Oficial de la Sociedad Espanola Nefrologia 24 Suppl (6): 91
Kes, P.; Slavicek, J. 2013: Hepatitis C virus and chronic progressive kidney disease. Guidelines for detection, evaluation, treatment and prevention of infection transmission in hemodialysis units; procedure for infected patients-candidates for kidney transplantation and procedure for patients suspected of HCV infection-related kidney disease Acta Medica Croatica: Casopis Hravatske Akademije Medicinskih Znanosti 67(4): 361-366
Goicoechea, M.A. 2004: Cardiovascular disease in patients with 4 and 5 stage chronic kidney disease. Patient in chronic dialysis Nefrologia: Publicacion Oficial de la Sociedad Espanola Nefrologia 24 Suppl (6): 142-160; 187-235
Chitalia, N.; Raja, R.B.; Bhandara, T.; Agrawal, P.; Kaski, J.C.; Jha, V.; Banerjee, D. 2010: Serum adiponectin and cardiovascular risk in chronic kidney disease and kidney transplantation Journal of Nephrology 23(1): 77-84
Di Iorio, B.R.; Marzocco, S.; Nardone, L.; Sirico, M.; De Simone, E.; Di Natale, G.; Di Micco, L. 2017: Urea and impairment of the Gut-Kidney axis in Chronic Kidney Disease Giornale Italiano di Nefrologia: Organo Ufficiale Della Societa Italiana di Nefrologia 34(Nov-Dec)
Topchii, I.I.; Kirienko, A.N.; Kirienko, D.A.; Yakovtsova, I.I.; Gavriluk, A.A.; Danyliuk, S.V.; Ivakhno, I.V.; Tovazhnianska, V.D. 2019: Features of endothelium morphological structure in kidney vessels, coronary arteries and aorta during chronic kidney disease Wiadomosci Lekarskie 72(7): 1269-1273
Thanakitcharu, P.; Jitsuparat, Y.; Jirajan, B. 2017: Prevalence of Arterial Stiffness and Associated Factors in Thai Patients with Chronic Kidney Disease and Kidney Transplant Recipients Journal of the Medical Association of Thailand 100(Suppl 1): S56-S69
Böör, A.; Jurkovic, I.; Havierová, Z.; Kocan, P. 2010: Prolonged treatment of chronic renal insufficiency, acquired cystic kidney disease, simultaneous precancerous lesions and multiple tumors of left kidney Ceskoslovenska Patologie 46(4): 105-110
Guilhot, F. 1993: Interferon alfa and low-dose cytosine-arabinoside for the treatment of patients with chronic myelogenous leukemia in chronic phase. French CML Study Group Seminars in Hematology 30(3 Suppl 3: 24-25
Basile, C. 2008: The long-term prognosis of acute kidney injury: acute renal failure as a cause of chronic kidney disease Journal of Nephrology 21(5): 657-662
Azzalini, L.; Laricchia, A.; Regazzoli, D.; Mitomo, S.; Hachinohe, D.; Bellini, B.; Demir, O.M.; Poletti, E.; Maccagni, D.; Colombo, A. 2019: Ultra-Low Contrast Percutaneous Coronary Intervention to Minimize the Risk for Contrast-Induced Acute Kidney Injury in Patients with Severe Chronic Kidney Disease Journal of Invasive Cardiology 31(6): 176-182